CLIMATE试验方案:比较Luminal Index与标准MRI对前列腺癌加速检测的诊断准确性
CLIMATE是一项前瞻性、多中心、配对、非随机对照试验,旨在比较Luminal Index MRI(LI-MRI)与标准治疗MRI(多参数或双参数MRI)对临床显著前列腺癌(csPCa)的诊断准确性,以靶向活检为参考标准。受试者为临床怀疑前列腺癌且未经诊断或治疗的成年男性,每人在单次扫描中完成两种MRI并独立判读。
要点
- LI-MRI基于多回波T2加权序列,扫描时间不足10分钟。
- 主要终点为两种MRI对csPCa的每受试者诊断准确性比较。
- MRI评分≥3的疑似病灶将进行靶向活检作为参考标准。
核心结论
- CLIMATE试验将评估LI-MRI与标准MRI对临床显著前列腺癌的诊断准确性差异。
研究设计与样本
- 前瞻性、多中心、配对、非随机比较试验,比较LI-MRI与标准MRI靶向活检。
- 纳入年龄≥18岁、临床怀疑前列腺癌且无既往诊断或治疗的成年男性。
- 每名受试者在单次扫描中先后完成LI-MRI和标准MRI,两种检查互盲判读。
关键数值与推荐
- LI-MRI基于多回波T2加权序列,检查时间不足10分钟。
- 两种MRI均采用1-5分怀疑度评分(Likert量表或PI-RADS)。
- MRI评分≥3的疑似病灶进行靶向活检,作为参考标准。
- 主要终点为以靶向活检为参考标准,比较两种MRI对csPCa的每受试者诊断准确性。
临床怎么用
- 若LI-MRI诊断准确性不劣于标准MRI,其不足10分钟的扫描时间可能加速前列腺癌检测流程。
局限性
- 原文指出LI-MRI在前列腺癌诊断评估中的诊断性能证据尚缺乏。
- 试验为非随机设计,采用配对比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVES: Luminal Index magnetic resonance imaging (LI-MRI) is a novel technique that has recently been proposed for prostate cancer (PCa) characterisation. It is based on multi-echo T2-weighted sequences and requires <10 min to be performed. However, evidence on its diagnostic performance in the diagnostic evaluation of PCa is lacking. The 'Comparison of diagnostic accuracy of Luminal Index and standard of care MRI for Accelerated deTEction of prostate cancer' (CLIMATE) trial aims to compare the diagnostic accuracy of LI-MRI and standard of care (SOC) MRI (multiparametric or biparametric MRI) for the detection of clinically significant PCa (csPCa). TRIAL DESIGN: The CLIMATE trial is a prospective, multicentre, paired, non-randomised comparative trial of LI-MRI and SOC MRI targeted biopsy in participants with clinically suspected PCa. ENDPOINTS: The primary endpoint of the trial is to compare the per-participant diagnostic accuracy of LI-MRI and SOC MRI for csPCa using targeted biopsies as the standard of reference. PATIENTS AND METHODS: Adult men (aged ≥18 years) with clinical suspicion of PCa and no prior PCa diagnosis or treatment will be invited. Each participant will undergo LI-MRI and SOC MRI in a single scan session, with each test interpreted without knowledge of the other test images or results. LI-MRI and SOC MRI will be reported on a 1-5 scale for suspicion of tumour (Likert scale or Prostate Imaging-Reporting and Data System). Targeted biopsies will be taken for any suspicious lesions detected, defined as MRI score of ≥3. TRIAL REGISTRATION: ClinicalTrials.gov Registry (NCT05020522).
引用
- Al-Hammouri T, Brembilla G, Brizmohun M, et al. The 'Comparison of diagnostic accuracy of Luminal Index and standard of care MRI for Accelerated deTEction of prostate cancer' (CLIMATE) trial protocol. BJU Int. 2026. PMID: 41582606. doi:10.1111/bju.70108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。